Sage Represents DBM: An Opportunity to Acquire or Partner with a Revenue Generating Pre-Clinical CRO
The Sage Group is pleased to announce it is representing Discovery Biomed (“DBM”; https://discoverybiomed.com/). DBM is a revenue-generating pre-clinical CRO based in Birmingham, Alabama focused on integrating biologically- and disease-relevant human cell cultures and lines into all relevant steps of Drug Discovery.
Please request from Sage a non-confidential Information Memorandum on DBM.
DBM is the one of the first companies to enable extension of preclinical testing to human cells and cell models including those derived from both healthy and diseased tissue. DBM owns a defined niche in the Humanized Drug Discovery space that sets them apart from the competition in the creation and bioassay of normal and diseased human cell platforms.